Given the role of EVs in transferring oncogenic signals, reducing p-EGFR packaging into EVs may limit the ability of tumor-derived EVs to propagate EGFR-driven signaling, potentially contributing to the therapeutic effects of TKIs. The gene discussed is EGFR; the disease is neoplasm.